Compare · AEMD vs MDLN
AEMD vs MDLN
Side-by-side comparison of Aethlon Medical Inc. (AEMD) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AEMD and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 27453.8x AEMD ($1.7M).
- MDLN has been more active in the news (12 items in the past 4 weeks vs 7 for AEMD).
- MDLN has more recent analyst coverage (25 ratings vs 2 for AEMD).
- Company
- Aethlon Medical Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $1.7M
- $46.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 7
- 12
- Recent ratings
- 2
- 25
Aethlon Medical Inc.
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Latest AEMD
- SEC Form PRE 14A filed by Aethlon Medical Inc.
- Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream
- Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream
- SEC Form 10-Q filed by Aethlon Medical Inc.
- Aethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program
- Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026
- Aethlon Medical Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Presenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live stream
- Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.